World Pancreatic Cancer Market Spotlight 2021-2031: Key Marketed and Pipeline Drugs, Events, Clinical Trials, Regulations, Disease Prevalence, Licensing and Acquisition, Revenue – ResearchAndMarkets.com

World Pancreatic Cancer Market Spotlight 2021-2031: Key Marketed and Pipeline Drugs, Events, Clinical Trials, Regulations, Disease Prevalence, Licensing and Acquisition, Revenue – ResearchAndMarkets.com




World Pancreatic Cancer Market Spotlight 2021-2031: Key Marketed and Pipeline Drugs, Events, Clinical Trials, Regulations, Disease Prevalence, Licensing and Acquisition, Revenue – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Pancreatic Cancer” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The report estimates that in 2019, there were 462,100 incident cases of pancreatic cancer worldwide, and expects that number to increase to 486,300 incident cases by 2028.

The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, poly ADP-ribose polymerase, dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor. These drugs are commonly administered via the intravenous route, with a few select products being available in oral and intratumoral formulations.

The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II. Therapies in development for pancreatic cancer focus on a wide variety of targets. The majority of pipeline drugs for pancreatic cancer are administered via the oral or intravenous routes.

High-impact upcoming events for drugs in the pancreatic cancer space comprise topline Phase II/III, Phase II, and Phase III trial results, and an expected patent expiration.

The overall likelihood of approval of a Phase I pancreatic cancer asset is 2%, and the average probability a drug advances from Phase III is 13.8%. Drugs, on average, take 10.7 years from Phase I to approval, compared to 9.5 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for pancreatic cancer have been in the early and mid-phases of development, with 93% of trials in Phase I-II, and only 7% in Phase III-IV.

The US has a substantial lead in the number of pancreatic cancer clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the pancreatic cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for pancreatic cancer, with 103 trials.

Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for pancreatic cancer, followed by Roche

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Surgery
  • Ablation or embolization
  • Radiation therapy
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy
  • Drugs used specifically for the treatment of PNETs

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Motixafortide for Pancreatic Cancer (January 24, 2020)
  • Lynparza for Pancreatic Cancer (December 17, 2019)
  • Pegilodecakin for Pancreatic Cancer (October 16, 2019)
  • Acelarin for Pancreatic Cancer (August 20, 2019)
  • Mavorixafor for Pancreatic Cancer (July 17, 2019)
  • Napabucasin for Pancreatic Cancer (July 1, 2019)
  • Abraxane for Pancreatic Cancer (June 2, 2019)
  • Lynparza for Pancreatic Cancer (June 2, 2019)
  • NanoKnife System for Pancreatic Cancer (May 13, 2019)
  • MVT-5873 for Pancreatic Cancer (May 8, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Lynparza Gets US OK For Pancreatic Cancer

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Cytocom Goes Public Via Merger With Cleveland BioLabs
  • Exact Goes All-In On Multi-Cancer Screening With $2.15Bn For Thrive; $410M For Base Genomics
  • TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens
  • Processa Licenses IP For Next-Generation Irinotecan From Aposense
  • Bristol Myers Squibb declines to exercise Agios Pharmaceuticals opt-in right for AG-270
  • DeMelle Licenses Pancreatic Cancer Candidate From Moffit
  • Taiho Acquires Asian Rights To Arcus IO Candidate
  • Tyme, Eagle Collaborate On Development Of Pancreatic Cancer Drug
  • Astellas Taps Pandion In Pancreas Immunomodulator Deal

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/3pyfsy

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900